Shares of Protara Therapeutics Inc. (TARA) are down nearly 32% from their 52-week high of $7.82, recorded last November, and trade around $5.
Protara is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases. Its lead drug candidate is TARA-002, which is derived from an inactivated Group A Streptococcus pyogenes bacterium, specifically type 3, strain SU.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.